Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring

Shifeng Li1, Hong Xu2, Shupeng Liu3

  • 1National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.

Insights

Monocyte-derived macrophages (MoMacs) drive pulmonary fibrosis. This study reveals immature Spp1hiMacs in silicosis, linking mitochondrial damage via Lp-PLA2 to impaired differentiation and fibrosis progression.

Area of Science:

  • Pulmonary fibrosis research
  • Macrophage biology
  • Silicosis pathogenesis

Background:

  • Monocyte-derived macrophages (MoMacs) are key in pulmonary fibrosis.
  • MoMac differentiation and mechanisms in silicosis are not fully understood.

Purpose of the Study:

  • To characterize MoMac differentiation in silicosis.
  • To elucidate mechanisms of MoMac-driven fibrosis.
  • To evaluate Lp-PLA2 inhibition for silicosis therapy.

Main Methods:

  • Integrated single-cell and spatial transcriptomics.
  • Analysis of the Lp-PLA2-ALCAT1-CL signaling pathway.
  • In vivo murine model of silica-induced pulmonary fibrosis.

Main Results:

  • Identified Spp1hiMacs as immature MoMacs in silicosis.
  • Demonstrated Lp-PLA2-induced mitochondrial and lysosomal dysfunction.
  • Showed darapladib ameliorates silica-induced pulmonary fibrosis in mice.

Conclusions:

  • Silicosis involves impaired MoMac differentiation via mitochondrial damage.
  • The Lp-PLA2 pathway is a critical mediator of fibrosis.
  • Lp-PLA2 inhibition offers a potential therapeutic strategy for silicosis.